

Curriculum Vitae

Professor Ian A Pearce

MB ChB BSc FRCOphth

Consultant Ophthalmologist/Vitreoretinal Surgeon

Director of Clinical Eye Research Centre

St Paul's Eye Unit

Royal Liverpool University Hospital

Honorary Professor of Clinical Ophthalmology

Department of Eye and Vision Science

University of Liverpool

Contents

	Page
Personal Details	3
Qualifications	
Current Post	
Current Roles	4
Consultant Clinical Role	
Director of Clinical Eye Research Centre Role	
Professional/Learned Society Appointments	5
Grants	6
Clinical Collaboration with University of Liverpool	7
National/International Study Committee Membership	8
Awards	9
Postgraduate	
Undergraduate	
Publication List	
National Guidelines	10
Book Chapters	10
Peer Reviewed Publications	11
National/International Invited Lectures	18
Referees	22

Personal

Name	Ian Andrew Pearce
Address	St Paul's Eye Unit Royal Liverpool University Hospital Liverpool L7 8XP
NHS Secretary Tel Number	0151 706 3991
Email	ian.pearce@rlbuht.nhs.uk

Qualifications

1984 - 1990 University of Liverpool	BSc (Physiology) MB ChB (distinction in physiology)
Post-graduation	FRCOphth 1994

Current Post

January 2002 - Present	Consultant Ophthalmologist Director Of Clinical Eye Research Centre Medical and Surgical Retinal Services St Paul's Eye Unit Royal Liverpool University Hospital Liverpool L7 8XP
-------------------------------	--

Consultant Ophthalmologist Clinical Role

St Paul's Eye Unit is one of the UK's leading centres for the management of medical and surgical retinal conditions and has an international reputation for research in these areas. I provide secondary and tertiary referral services for vitreoretinal surgery (VR), age-related macular disease (AMD) and diabetic eye disease (DR) and am clinical lead for the uveitis service.

The VR fellowship program is highly regarded as one of the most attractive training schemes in Europe attracting and training > 30 post accredited leading national and international ophthalmic surgeons in the most contemporary management of vitreoretinal surgical disorders.

Through my extensive clinical and research experience in a wide range of retinal disorders I have been invited as clinical expert advisor to NICE for several novel drug appraisals and medical innovation developments which have revolutionized the management of ocular conditions in the past decade.

As well as delivering regular national and international invited lectures I sit and advise on several national committees including the Royal College of Ophthalmologists' Professional Standards and Scientific Committees, the Joint Royal Colleges of Physicians Training Board SAC for Medical Ophthalmology, the DH ACDP CJD Sub-Committee and the DVLA Visual Standards Panel.

Director of Clinical Eye Research Centre Role

I am Honorary Professor in Clinical Ophthalmology at the University of Liverpool supporting/supervising PhD students and academic lead for student NICE champions.

In my role as Director of the Clinical Eye Research Centre I am responsible for promoting, approving, advising and managing resource allocation to a range of commercially and externally funded clinical trials each with their own principal investigator. At present 27 ongoing trials with annual income >300K allow access for patients to cutting edge treatment through local, national and international Phase I/II/III trials. In addition, the unit supports oncology/haematology sponsored studies that require ophthalmic input and Phase I trials through collaboration with the MHRA Phase I accredited Clinical Research Unit.

A key aspect of the role is to support and promote effective translational research with the University of Liverpool's Department of Eye and Vision Science. As well as supporting individual studies I am clinical collaborator on several Engineering and Physical Sciences Research Council grants/ fellowships which have dedicated translational research objectives to provide drug/cell delivery to patients suffering with ophthalmic conditions. The success of CERC was one of the key motivators for St Paul's Eye Unit being awarded Freedom of the City of Liverpool and in 2018 we received the NIHR North West Coast Clinical Research Team of the Year award.

As well as being the Principal investigator for 8 studies in the past 5 yrs with income to the trust of >500K I was Chief UK Investigator for 15 centre trial of Lucentis in Diabetic macular oedema and I am the Chief UK Investigator for the Apellis APL2 study in Geographic atrophy. I advise on steering committees of several national and international studies and have worked closely with industry partners as the UK representative to global initiatives such as the Bayer Vision Academy, the Roche European/Canadian Ang-2 advisory committee, the Novartis Acuity Board and the IFA DR Barometer project in the past decade to identify unmet research needs in ophthalmology, develop clinical trials, develop global consensus guidance and share best practice to improve patient management.

Professional/Learned Society Appointments

Director of Clinical Eye Research Centre, St Paul's Eye Unit (2014 to date)

RCOPHTH Regional Advisor Mersey Region (2011 to 2019)

RCOPHTH Regional Representative Mersey Region (2019 to 2022)

RCOPHTH Member of Professional Standards Committee (2015 to date)

RCOPHTH Representative to DVLA Vision Standards Panel (2015 to date)

RCOPHTH Member of Scientific Committee (2007 to 2016)

Joint Royal College of Physicians' Training Board Member SAC for Medical Ophthalmology (2010 to date)

Chair of ACDP TSE Working Group Ophthalmic Subgroup (2008 to date)

CMO appointed Expert Advisor to UK CJD Incidents Panel (2006 to 2013)

Programme Director for Medical Ophthalmology Mersey Deanery (2009 to date)

Assistant Programme Director for Ophthalmology Mersey Deanery (2006 to 2011)

MHRA specialist advisor novel VR instruments/investigations/studies. (2014 to date)

Nominated Clinical Expert for NICE Technology Appraisals of :

- Dexamethasone implant for Retinal vein occlusion TA229 (July 2011)
- Ranibizumab in Retinal vein occlusion TA 283 (May 2013)
- Ocriplasmin for vitreomacular traction TA 297 (Oct 2013)
- Aflibercept in Retinal vein occlusion TA 305 (Feb 2014)
- Aflibercept for diabetic macular oedema TA 346 (Jan 2015)
- Dexamethasone implant for diabetic macular oedema TA 349 (Jan 2015)
- Faricimab for Age-related Macular Degeneration (ID3899 May 2022)
- Faricimab for diabetic macular oedema (ID3898 May 2022)

Invited Clinical Expert for Economic Review Group (ERG) submission for NICE Technology Appraisal of :

- Dexamethasone implant for non-infectious uveitis TA460 (July 2017)
- Adalimumab anti-TNF treatment for non-infectious uveitis TA460 (July 2017)

Invited Clinical Expert for NICE Medtech Innovation Briefing :

- Noctura Sleep Mask for diabetic retinopathy/macular oedema MIB144 (Apr 2018)
- Eyemax mono Intraocular lens for AMD MT384 (May 2018)

President of Ophthalmic Imaging Society (2009 to 2013)

Grants

NIHR Portfolio Studies

VELODROME Port Delivery Study (2021) NCT04657289
Chief UK Investigator and Principal Investigator

PORTAL Extension Study for the Port Delivery System With Ranibizumab (2021)
NCT03683251
Chief UK Investigator and Principal Investigator

CANBERRA Study (2021) NCT04265261
Chief UK Investigator and Principal Investigator

OAKS Study APL-2 in Geographic Atrophy Interventional (2019) NCT03525613
Chief UK Investigator and Principal Investigator

RAPTOR/RAVEN Brolocizumab Study (2019) NCT03802630 / NCT03810313
Chief UK Investigator and Principal Investigator

SAFARI Phase IV Observational Study (2018) NCT02161575
National Steering Committee Member and Principal Investigator

POLARIS Observational Study (2018) NCT01771081
International Steering Committee Member and Principal Investigator

OCTANE Study (2017)
Steering Committee Member and Principal Investigator

AZURE Phase IIIb Interventional Study (2017) EudraCT number 2013-000120-33
Principal Investigator

SAFARI Phase IV Observational Study (2016) NCT02161575
Steering Committee Member and Principal Investigator

JETREA M13-056 Phase IV Interventional RCT (2016) NCT02035748
Principal Investigator

SPECTRI Phase III Interventional RCT (2015) NCT02247531
Principal Investigator

RELIGHT Phase IV Interventional Study (2014) NCT01257815
Chief UK Investigator and Principal Investigator

LUMINOUS Phase IV Observational Study (2013) NCT01318941
Principal Investigator

ENDURE Phase III Interventional Uveitis (2012) RCT NCT01090310
Principal Investigator

Novartis Research Fellow Grant 2012

Supervisor

DEGAS Phase II Interventional DMO RCT (2011) NCT00701181

Principal Investigator

CABERNET Phase III Interventional AMD RCT (2011) NCT00454389

Principal Investigator

LUMINATE Phase III Interventional Uveitis RCT (2010) NCT01243983

Principal Investigator

POSURDEX Phase III Interventional RVO (2008) Study NCT00701181

Principal Investigator

Wellcome Trust Research Fellow 1996

Clinical Collaborations with University of Liverpool

Department of Eye and Vision Science

Clinical Lead for Novel Intercalated MSC in Clinical Ophthalmology and Vision Science (COVIS) 2021 – to date

Along with Prof Rachel Williams, as Academic Lead, I developed, refined and introduced a new MSc Program to the University of Liverpool aimed at intercalating medical students providing the opportunity to develop in depth applied knowledge, clinical practice, research skills and professional behaviours in the connected fields of Clinical Ophthalmology and Vision Science. The COVIS MSc Programme launched in Sep 2021 with its first students and hopes to continue to attract high quality aspiring ophthalmology physicians and researchers.

EPSRC Health Impact Partnership 2017 (Dr Victoria Kearns)

Collaborator - in-kind support (£2,250 over 3 years). Commitment to monthly meeting for 3 years to discuss project results, patient engagement, regulatory issues and routes to development. Also training in intravitreal injections in wet lab.

EPSRC Future Manufacturing theme - Medical Devices Hub 2018 (Prof Rachel Williams)

UKRI EPSRC Future Manufacturing Research Hub in 21st century devices
Support as a clinical project partner - in-kind support (£6k). Commitment to attendance at an annual HUB meeting and UoL monthly meeting providing expert advice on future developments of ophthalmology medical devices, on their clinical relevance and to support the translation into clinical practice

EPSRC fellowship - NHFP 2018 (Dr Atikah Haneef)

Novel bioengineering for auto-integration of advanced cell delivery substrates

Total grant awarded: £654,958

Clinical collaborator - in-kind support £4,000 pa for 3 years. Commitment to meet team every two months to discuss projects results, provide guidance on end-user requirements, and clinical relevance and applicability. Provide surgical training in wet lab to the team on sub-retinal insertion to assist in ex-vivo studies and facilitate the team's interaction with patient engagement groups and patient experts.

Linbury Trust /Foundation for the Prevention of Blindness Grant 2018 (Dr Victoria Kearns)

Transplanting cells to the retina

Total grant awarded £449,775

Clinical collaborator - in-kind support for 3 years. Support for Clinical PhD student
Commitment to meet regularly to discuss projects results, provide guidance on end-user requirements, and clinical relevance and applicability. Provide surgical training in wet lab

to the team on sub-retinal insertion to assist in ex-vivo studies and facilitate the team's interaction with patient engagement groups and patient experts.

National/International Study Committee Membership

CANBERRA Study (Diabetic Retinopathy) NCT04265261

Chief UK Investigator and Principal Investigator

RAPTOR/RAVEN Brolucizumab Study (Retinal Vein Occlusion) NCT03802630 / NCT03810313

Chief UK Investigator and Principal Investigator

VELODROME Port Delivery Study (AMD) NCT04657289

Chief UK Investigator and Principal Investigator

OAKS Study APL-2 in Geographic Atrophy Interventional RCT NCT03525613

Chief UK Investigator and Principal Investigator

RELIGHT Phase IV Interventional Study NCT01257815

Chief UK Investigator and Principal Investigator

SAFARI Phase IV Observational Study NCT02161575

National Steering Committee Member and Principal Investigator

POLARIS Observational Study NCT01771081

International Steering Committee Member and Principal Investigator

BRIGHTER Interventional RCT NCT01599650

International Steering Committee Member

CRYSTAL Interventional Phase IIIb Study NCT01535261

International Steering Committee Member

DIAMONDS Interventional RCT NIHR HTA 13/142/04

National Steering Committee Member

GMAN Interventional RCT ISRCTN34221234

Member of Safety Data Monitoring Committee

Awards

Postgraduate Awards

NIHR North West Coast Clinical Research Team of the Year (2018)

National Clinical Excellence Award - Silver Award (2017)

American Academy of Ophthalmology Best Research Poster Presentation (2011)
“Evaluation of individual patient ranibizumab treatment based on a visual acuity stability concept in retinal vein occlusion patients.”

Ophthalmic Imaging Association Scientific Symposium Best Speaker Award (2008)

RCOPHTH Lecturer Award (2006)

North of England Ophthalmological Society Trainees Prize - Best Paper (1999)
“ Three year visual outcome for treated stage 3 retinopathy of prematurity (ROP): Cryotherapy versus laser. BJO 1998; 82:1254 – 1259 ”

North of England Ophthalmological Society Trainees Prize - Best Paper (1997)
“Does cryotherapy before drainage increase the risk of intraocular haemorrhage and affect outcome? BJO 1997; 81:563 – 567 ”

Royal Society of Medicine: Ophthalmology Section Trainees Prize - Best Paper (1997)
“ Trends in management of Stage 3 ROP: Cryotherapy versus laser.”

Royal Society of Medicine: Ophthalmology Section Trainees Prize – Finalist (1998)
“A new technique for posterior subtenon steroid injection in the management of cystoid macular oedema”

Foulds Trophy Session, Royal College of Ophthalmologists Annual Congress - Finalist (1997)
“Visual function after macular hole surgery.”

Undergraduate Awards

E.B. Noble Prize for Anatomy (1986)

Robert Gee Undergraduate Scholarship (Highest Pre-clinical Results 1986)

Distinction in Physiology (1986)

Medical Research Council Undergraduate Scholarship (BSc Research Project 1987)

Wellcome Trust Research Scholarship (BSc Research Project extension 1987)

Publication List

National Guidelines

Principal Author

Managing CJD/vCJD risk in Ophthalmology October 2009
(<http://www.dh.gov.uk/ab/ACDP/TSEguidance/index.htm>)

Co-Author

National RCOphth (UK) Guidelines for Intravitreal Injections Procedure 2009
(<http://www.rcophth.ac.uk/docs/scientific/IVTRrevisionfinal2009.pdf>)

Co-Author

Guidelines for Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment 2008
(http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf)

Book Chapters

Medical therapies for diabetic eye diseases- how good are they ?

Pearce IA and Harding SP

Chapter 18 of Evidenced-based Management of Diabetes. 2012 TFM Publishing

Scleral Perforations

Konstanidis L and **Pearce IA**

Chapter 5 of Complications of Vitreo-Retinal Surgery. 2013 Lippincott, Williams & Wilkins

Ophthalmology

Pearce IA

Barton and Power's Clinical Negligence, 2015 Bloomsbury Press

Peer-Reviewed Publications

>80 peer reviewed publications cited over 1000 times. h- index of 23

Clinical Outcomes of Observed and Treated Acute Posterior Multifocal Placoid Pigment Epitheliopathy and Relentless Placoid Chorioretinitis.

Step toe PJ, **Pearce I**, Beare NAV, Sreekantham S, Mohammed BR, Barry RJ, Denniston AK, Murray PI. Ocul Immunol Inflamm. 2023 May 3:1-7.

A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration:

PRECISE Study Report 1.

Chorev M, Haderlein J, Chandra S, Menon G, Burton BJL, **Pearce I**, McKibbin M, Thottarath S, Karatsai E, Chandak S, Kotagiri A, Talks J, Grabowska A, Ghanchi F, Gale R, Hamilton R, Antony B, Garnavi R, Mareels I, Giani A, Chong V, Sivaprasad S. J Clin Med. 2023 Apr 20;12(8):3013.

Visual acuity time in range: a novel concept to describe consistency in treatment response in diabetic macular oedema.

Kozak I, **Pearce I**, Cheung CMG, Machewitz T, Lambrou GN, Molina D, Suleiman L, Youssef H, Bressler NM. Eye (Lond). 2023 Mar 28. Online ahead of print.

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.

Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; **YOSEMITE and RHINE Investigators**. Jpn J Ophthalmol. 2023 Mar 10:1-16. Online ahead of print.

Study protocol on prevalence of non-exudative macular neovascularisation and its contribution to prediction of exudation in fellow eyes with unilateral exudative AMD (EYE-NEON).

Thottarath S, Chandra S, Gurudas S, Tsai WS, Giani A, De Cock E, Yamaguchi TCN, Sivaprasad S; **EYENEON Study Group**. Eye (Lond). 2023 Mar 7. Online ahead of print.

Associations with visual acuity outcomes after 12 months of treatment in 9401 eyes with neovascular AMD.

Relton SD, Chi GC, Lotery A, West RM; **Real world AMD treatment outcomes EMR User Group**; McKibbin M. BMJ Open Ophthalmol. 2022 Jun;7(1)

Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study.

Casswell EJ, Cro S, Cornelius VR, Banerjee PJ, Zvobgo TM, Tudor Edwards R, Ezeofor V, Anthony B, Shahid SM, Bunce C, Kelly J, Murphy C, Robertson E, Charteris D; **ASCOT Investigator Study Group**. Br J Ophthalmol. 2023 Feb 27: Online ahead of print.

The changing landscape for the management of patients with neovascular AMD: brolicizumab in clinical practice.

Pearce I, Amoaku W, Bailey C, Downey L, Gale R, Ghanchi F, Hamilton R, Mahmood S, Menon G, Nosek J, Talks J, Yang Y. Eye (Lond). 2022 Sep;36(9):1725-1734

Associations with baseline visual acuity in 12,414 eyes starting treatment for neovascular AMD.

Relton SD, Chi GC, Lotery AJ, West RM; **Real world AMD treatment outcomes EMR User Group**; McKibbin M. Eye (Lond). 2022 Aug 26. Online ahead of print.

Recommendations for OCT Angiography Reporting in Retinal Vascular Disease: A Delphi Approach by International Experts.

Munk MR, Kashani AH, Tadayoni R, Korobelnik JF, Wolf S, Pichi F, Koh A, Ishibazawa A, Gaudric A, Loewenstein A, Lumbroso B, Ferrara D, Sarraf D, Wong DT, Skondra D, Rodriguez FJ, Staurengi G, **Pearce I**, Kim JE, Freund KB, Parodi MB, Waheed NK, Rosen R, Spaide RF, Nakao S, Sadda S, Vujosevic S, Wong TY, Murata T, Chakravarthy U, Ogura Y, Huf W, Tian M. Ophthalmol Retina. 2022 Sep;6(9):753-761

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.

Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, **Pearce IA**, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Lancet. 2022 Feb 19;399(10326):741-755.

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; **TENAYA and LUCERNE Investigators**. Lancet. 2022 Feb 19;399(10326):729-740.

Lessons of the month 2: Retinal vasculitis: a first presentation of Takayasu's arteritis.

Ibrahim H, D'souza S, Agorogiannis E, Ali A, Bashar N, **Pearce I**, Madhusudhan S. Clin Med (Lond). 2021 Nov;21(6):e673-e676.

Predictive Association of Pre-Operative Defect Areas in the Outer Retinal Layers With Visual Acuity in Macular Hole Surgery.

Baumann C, Iannetta D, Sultan Z, **Pearce IA**, Lohmann CP, Zheng Y, Kaye SB. Transl Vis Sci Technol. 2021 Apr 1;10(4):7

Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan.

Steinle NC, **Pearce I**, Monés J, Metlapally R, Saroj N, Hamdani M, Ribeiro R, Rosenfeld PJ, Lad EM. Am J Ophthalmol. 2021 Jul;227:116-124.

Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure

Jean-François Korobelnik, Anat Loewenstein, Bora Eldem, Antonia M. Joussen, Adrian Koh, George N. Lambrou, Paolo Lanzetta, Xiaoxin Li, Monica Lövestam-Adrian, Rafael

Navarro, Annabelle A. Okada, **Ian Pearce**, Francisco J. Rodríguez, David T. Wong, Lihteh Wu. Graefes Arch Clin Exp Ophthalmol. 2021; 259(3): 567–574

Pachychoroid: current concepts on clinical features and pathogenesis.

Castro-Navarro V, Behar-Cohen F, Chang W, Jousseaume AM, Lai TYY, Navarro R, **Pearce I**, Yanagi Y, Okada AA. Graefes Arch Clin Exp Ophthalmol. 2020 Oct 15

The impact of COVID policies on the vitreoretinal service in St Paul's Eye Unit, Liverpool. Dervenis N, Heimann H, Hussain RN, Chua PY, Sandinha T, Vilà N, **Pearce I**, Groenewald C, Tan SZ. Eye (Lond). 2020 Jul 24;1-2

Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study.

Pearce I, Clemens A, Brent MH, Lu L, Gallego-Pinazo R, Minnella AM, Creuzot-Garcher C, Spital G, Sakamoto T, Dunger-Baldauf C, McAllister IL; all the LUMINOUS™ study investigators. PLoS One. 2020 Jun 18;15(6)

Providing a Safe and Effective Intravitreal Treatment Service: Strategies for Service Delivery.

Amoaku W, Bailey C, Downey L, Gale RP, Ghanchi F, Hamilton R, Mahmood S, Menon G, Nosek J, **Pearce I**, Yang Y. Clin Ophthalmol. 2020 May 15;14:1315-1328

Optimisation of a Novel Bio-Substrate as a Treatment for Atrophic Age-Related Macular Degeneration.

McCormick R, **Pearce I**, Kaye S, Haneef A. Front Bioeng Biotechnol. 2020 May 15;8:456

Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic.

Korobelnik JF, Loewenstein A, Eldem B, Jousseaume AM, Koh A, Lambrou GN, Lanzetta P, Li X, Lövestam-Adrian M, Navarro R, Okada AA, **Pearce I**, Rodríguez FJ, Wong DT, Wu L. Graefes Arch Clin Exp Ophthalmol. 2020 Jun;258(6):1149-1156

Fundamental principles of an effective diabetic retinopathy screening program.

Lanzetta P, Sarao V, Scanlon PH, Barratt J, Porta M, Bandello F, Loewenstein A; **Vision Academy**. Acta Diabetol. 2020 Jul;57(7):785-798

Suspending treatment of neovascular age-related macular degeneration in cases of futility.

Wong DT, Lambrou GN, Loewenstein A, **Pearce I**, Okada AA. Retina. 2020 Jun;40(6)

Effect of inverted internal limiting membrane flap on closure rate, postoperative visual acuity, and restoration of outer retinal layers in primary idiopathic macular hole surgery.

Baumann C, Kaye S, Iannetta D, Sultan Z, Dwivedi R, **Pearce I**. Retina. 2020 Oct;40(10):1955-1963

Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedema.

Pearce I, Bailey C, Fletcher E, Ghanchi F, Rennie C, Santiago C, Napier J, Yang Y. Eye (Lond). 2020 May;34(5):969-981

Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.

Gale RP, **Pearce I**, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, Balaskas K, Burton BJL, Downes SM, Eleftheriadis H, George S, Gilmour D, Hamilton R, Lotery AJ, Patel N, Prakash P, Santiago C, Thomas S, Varma D, Walters G, Williams M, Wolf A, Zakri RH, Igwe F, Ayan F.

Br J Ophthalmol. 2020 Apr;104(4):493-499

Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema.

Chakravarthy U, **Pearce I**, Banerjee S, Burton BJL, Downey L, Gale R, Patel J, Patra S, Sivaprasad S, Stevenson M, Lupton S.

BMJ Open Ophthalmol. 2019 Apr 30;4(1)

Dexamethasone implant for non-infectious uveitis: is it cost-effective?

Squires H, Bermejo I, Poku EN, Cooper K, Stevens J, Hamilton J, Wong R, Denniston AK, **Pearce I**, Quhill FM.

Br J Ophthalmol. 2019 Nov;103(11):1639-1644.

Adalimumab for non-infectious uveitis: is it cost-effective?

Bermejo I, Squires H, Poku EN, Cooper K, Stevens JW, Hamilton J, Wong R, **Pearce I**, Quhill FM, Denniston AK.

Br J Ophthalmol. 2019 Nov;103(11):1633-1638

Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review.

Pearce IA, Simó R, Lövestam-Adrian M, Wong DT, Evans M.

Diabetes Obes Metab. 2019 Mar;21(3):467-478

The role of OCT-A in retinal disease management.

Rodríguez FJ, Staurenghi G, Gale R; **Vision Academy Steering Committee**.

Graefes Arch Clin Exp Ophthalmol. 2018 Nov;256(11):2019-2026

Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy.

Agorogiannis, EI, **Pearce IA**, Yadav S, Parry DG, Beare NAV.

Eye (Lond). 2018 Nov;32(11):1731-1739

A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS).

Stefanickova J, Cunha-Vaz J, Ulbig M, **Pearce I**, Fernandez -Vega Sanz A, Theodossiadis P, Kodjikian L, Izmailov A, Muston D, Vassilev Z, Lamotte B, Tückmantel C, Friedl S, Altemark A, Schwarz HJ, Katz T; POLARIS study investigators.

Acta Ophthalmol. 2018 Dec;96(8):e942-e949

A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults.

Squires H, Poku E, Bermejo I, Cooper K, Stevens J, Hamilton J, Wong R, Denniston A, **Pearce I**, Quhill F.

Health Technol Assess. 2017 Nov;21(68):1-170.

Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E, Das Gupta A, Wenzel A, **Pearce I**; BRIGHTER Study Group.
Ophthalmology. 2017;124(12):1778-1787.

Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians.
Yadav S, Parry DG, Beare NAV, **Pearce IA**.
Br J Ophthalmol. 2017;101(10):1377-1380.

Individualized Stabilization Criteria-Driven Ranibizumab Versus Laser in Branch Retinal Vein Occlusion: 6-Month Results Of BRIGHTER
Tadayoni R, Waldstein SM, Boscia F, Gerding H, **Pearce I**, Priglinger S, Wenzel A, Barnes E Gekkieva M, Pilz S, Monés J, on behalf of the BRIGHTER study group.
Ophthalmology 2016;123:1332-44

Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S, Stubbings W, **Pearce I**; CRYSTAL Study Group.
Ophthalmology 2016;123:1101-11

Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
Pearce I, Banerjee S, Burton BJ, Chakravarthy U, Downey L, Gale RP, Gibson J, Pagliarini S, Patel J, Sivaprasad S, Andrews C, Brittain C, Warburton J; RELIGHT Study Group.
Ophthalmology. 2015 Sep;122(9):1811-9

Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel.
Gerding H, Monés J, Tadayoni R, Boscia F, **Pearce I**, Priglinger S.
Br J Ophthalmol. 2015 Mar;99(3):297-304

Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review.
Glanville J, Patterson J, McCool R, Ferreira A, Gairy K, **Pearce I**.
BMC Ophthalmol. 2014 Jan 21;14:7.

Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
Jackson TL, Dugel PU, Bebhuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA; **CABERNET Study Group**.
Ophthalmology. 2013 Aug;120(8):1597-603.

Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
Dugel PU, Bebachuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL; **CABERNET Study Group**.
Ophthalmology. 2013 Feb;120(2):317-27

Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment study (SPR study): Risk assessment of anatomical outcome. SPR study report no. 7.
Feltgen N, Heimann H, Hoerauf H, Walter P, Hilgers RD, Heussen N; **Writing group for the SPR study investigators**.
Acta Ophthalmol. 2013 May;91(3):282-7.

Use of Staurenghi lens angiography in the management of posterior uveitis.
Reeves GM, Kumar N, Beare NA, **Pearce IA**.
Acta Ophthalmol. 2013 Feb;91(1):48-51

Owen ME, Beare NA, **Pearce IA**, Mewar D.
Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema.
Retina. 2012 Nov-Dec;32(10):2179; author reply 2179-80.

Retrospective review of 50 eyes with long-term silicone oil tamponade for more than 12 months.
Morphis G, Irigoyen C, Eleuteri A, Stappeler T, **Pearce I**, Heimann H.
Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):645-52.

Bilateral Viral Retinitis in A Patient With Immune Deficiency Because of Purine Nucleoside Phosphorylase Deficiency
Kumar A, Ziahosseini K, Saeed MU, **Pearce IA**, Beare NAV.
Retinal Cases & Brief Reports. 2012; 6(2):153-155

Cost-effectiveness of internal limiting membrane peeling versus no peeling for patients with an idiopathic full-thickness macular hole: results from a randomised controlled trial.
Ternent L, Vale L, Boachie C, Burr JM, Lois N; Full-Thickness Macular Hole and Internal Limiting Membrane Peeling Study (**FILMS**) **Group**.
Br J Ophthalmol. 2012 Mar;96(3):438-43

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Li J. **Ozurdex GENEVA Study Group**
Ophthalmology. 2011 Dec;118(12):2453-60.

Heavy silicone oil versus standard silicone oil in as vitreous tamponade in inferior PVR (HSO Study): interim analysis.
Joussen AM, Rizzo S, Kirchhof B, Schrage N, Li X, Lente C, Hilgers RD; **HSO -Study Group**.
Acta Ophthalmol. 2011 Sep;89(6):e483-9.

Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment study (SPR Study): predictive factors for functional outcome. Study report no. 6.
Heussen N, Feltgen N, Walter P, Hoerauf H, Hilgers RD, Heimann H; **SPR Study Group**.
Graefes Arch Clin Exp Ophthalmol. 2011 Aug;249(8):1129-36

Internal limiting membrane peeling versus no peeling for idiopathic full-thickness macular hole: a pragmatic randomized controlled trial.
Lois N, Burr J, Norrie J, Vale L, Cook J, McDonald A, Boachie C, Ternent L, McPherson G; Full-thickness Macular Hole and Internal Limiting Membrane Peeling Study (**FILMS**) **Group**.
Invest Ophthalmol Vis Sci. 2011 Mar 1;52(3):1586-92.

Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis associated uveitis.
Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, **Pearce I**.
Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):297-300.

Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect?
Marticorena J, Romano MR, Heimann H, Stappler T, Gibran K, Groenewald C, **Pearce I**, Wong D.
Br J Ophthalmol. 2011 Mar;95(3):391-5.

Incidence of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation.
Campa C, Harding SP, **Pearce IA**, Beare NA, Briggs MC, Heimann H.
Eye (Lond). 2010 Oct;24(10):1585-9

Dietary supplements in AMD – an Update.
Pearce IA.
RCOphth Focus Article Summer 2010

Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; **OZURDEX GENEVA Study Group**.
Ophthalmology. 2010 Jun;117(6):1134-1146

Paraneoplastic exudative retinal detachment associated with adenocarcinoma of the lung.
Burgess PI, Kenawy N, **Pearce IA**.
Eur J Ophthalmol. 2010 Feb 25.

Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease.
Gandhi JS, Tan LT, **Pearce I**, Charles SJ.
Eye (Lond). 2009 Mar;23(3):742-3.

Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment.

Amoaku W; National Institute for Health and Clinical Excellence; Royal College of Ophthalmologists (RCOphth); Department of Health; **Writing Committee** *Eye (Lond)*. 2009 Nov;23(11):2140-2.

[Densiron-68 heavy silicone oil in cases of PVR. Anatomic and functional outcomes].

Stappler T, Heimann H, Gibran SK, Groenewald C, **Pearce IA**, Wong D. *Ophthalmologe*. 2009 Apr;106(4):320-6.

Observational prospective study of the effectiveness in routine clinical practice of verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration. Murjane S, García-Fiñana M, Mahmood S, Lenfestey PM, Taylor SA, **Pearce IA**, Briggs MC, Heimann H, Harding SP. *Br J Ophthalmol*. 2009 Apr;93(4):468-73.

Uveitis triggered by acute onset gastroenteritis.

Cazabon S, Quah SA, **Pearce IA**, Harding SP. *Int J Clin Pract*. 2008 Dec;62(12):1957-8.

Cytomegalovirus retinitis in the absence of HIV or immunosuppression.

Sloan DJ, Taegtmeyer M, **Pearce IA**, Hart IJ, Miller AR, Beeching NJ. *Eur J Ophthalmol*. 2008 Sep-Oct;18(5):813-5.

Clinical and cost-effectiveness of internal limiting membrane peeling for patients with idiopathic full thickness macular hole. Protocol for a randomised controlled trial: FILMS (Full-thickness Macular Hole and Internal Limiting Membrane Peeling Study).

Lois N, Burr J, Norrie J, Vale L, Cook J, McDonald A; **Full-Thickness Macular Hole and Internal Limiting Membrane Peeling Study (FILMS) Group**. *Trials*. 2008 Nov 3;9:61.

Heavy tamponade 2 Densiron 68 in routine clinical practice: anatomical and functional outcomes of a consecutive case series.

Stappler T, Heimann H, Wong D, Gibran SK, Groenewald C, **Pearce IA**. *Eye (Lond)*. 2008 Oct;22(10):1360-5.

Primary vitrectomy with Densiron-68 for rhegmatogenous retinal detachment.

Romano MR, Stappler T, Marticorena J, Groenewald C, **Pearce I**, Gibran SK, Wong D, Heimann H. *Graefes Arch Clin Exp Ophthalmol*. 2008 Nov;246(11):1541-6.

Peel and peel again

Gibran SK, Flemming B, Stappler T, **Pearce I**, Groenewald C, Heimann H, Hiscott P, Wong D. *Br J Ophthalmol*. 2008 Mar;92(3):373-7.

The introduction of verteporfin photodynamic therapy in the UK: PDT users group (PDTUG) surveillance programme report 1.

Ghanchi FD, Fullarton J, Blake J, Harding SP; **PDTUG(UK)**.

Eye (Lond). 2008 May;22(5):671-7.

Glycaemic control and control of risk factors in diabetes patients in an ophthalmology clinic: what lessons have we learned from the UKPDS and DCCT studies?

Higgins GT, Khan J, **Pearce IA**.

Acta Ophthalmol Scand. 2007 Nov;85(7):772-6.

Early vitrectomy for fundus-obscuring dense vitreous haemorrhage from presumptive retinal tears.

Dhingra N, **Pearce I**, Wong D.

Graefes Arch Clin Exp Ophthalmol. 2007 Feb;245(2):301-4.

Kumar N, Sebastian R, Harding S, **Pearce I**.

Bevacizumab: a word of caution.

Can J Ophthalmol. 2007 Oct;42(5):760-1.

Successful retrieval of internal limiting membrane specimens.

Gibran SK, Prime W, Cazabon J, Stappler T, Heimann H, **Pearce I**, Groenewald C, Wong D, Hiscott P.

Eye (Lond). 2007 Feb;21(2):298-9.

Optimizing the use of tumornecrosis factor alpha inhibitors in refractory uveitis.

Sebastian RT, Harding SP, Bucknall RC, **Pearce IA**.

Arch Ophthalmol. 2006 Oct;124(10):1505

Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease.

Choudhary A, Harding SP, Bucknall RC, **Pearce IA**.

J Ocul Pharmacol Ther. 2006 Jun;22(3):168-75.

Can the sequential use of conventional silicone oil and heavy oil be a strategy for the management of proliferative vitreoretinopathy?

Wong D, Cazabon S, Ali H, Kumar I, Valldeperas X, Groenewald C, **Pearce I**.

Ann Acad Med Singapore. 2006 Mar;35(3):181-4.

Visual loss following removal of intraocular silicone oil.

Cazabon S, Groenewald C, **Pearce IA**, Wong D.

Br J Ophthalmol. 2005 Jul;89(7):799-802.

A pilot study on the use of a perfluorohexyloctane/silicone oil solution as a heavier than water internal tamponade agent.

Wong D, Van Meurs JC, Stappler T, Groenewald C, **Pearce IA**, McGalliard JN, Manousakis E, Herbert EN.

Br J Ophthalmol. 2005 Jun;89(6):662-5.

Dietary supplements in AMD

Pearce IA

RCOphth Focus Article Summer 2004

Vitreous penetration of levofloxacin in the uninflamed phakic human eye.

Herbert EN, **Pearce IA**, McGalliard J, Wong D, Groenewald C.

Br J Ophthalmol. 2002 Apr;86(4):387-9.

Pearce IA, Ilango B, Sells RA, Wong D.

Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant.

Br J Ophthalmol. 2000 Jul;84(7):736-40.

Pearce IA, McCready PM, Watson MP, Taylor RH.

Vertical diplopia following local anaesthetic cataract surgery: predominantly a left eye problem?

Eye (Lond). 2000 Apr;14 (Pt 2):180-4.

Valsalva retinopathy associated with blowing balloons.

Georgiou T, **Pearce IA**, Taylor RH.

Eye (Lond). 1999 Oct;13 (Pt 5):686-7.

Three year visual outcome for treated stage 3 retinopathy of prematurity: cryotherapy versus laser.

Pearce IA, Pennie FC, Gannon LM, Weindling AM, Clark DI.

Br J Ophthalmol. 1998 Nov;82(11):1254-9.

Visual function and patient satisfaction after macular hole surgery.

Pearce IA, Branley M, Groenewald C, McGalliard J, Wong D.

Eye (Lond). 1998;12 (Pt4):651-8.

Nasal epipapillary membrane causing visual field loss following macular hole surgery: does it throw fresh light on the retinotopic arrangement of the nerve fibre layer?

Groenewald CP, Wong D, **Pearce I**, Hiscott P, Grierson I.

Eye (Lond). 1998;12 (Pt 2):328-30.

Does cryotherapy before drainage increase the risk of intraocular haemorrhage and affect outcome? A prospective, randomised, controlled study using a needle drainage technique and sustained ocular compression.

Pearce IA, Wong D, McGalliard J, Groenewald C.

Br J Ophthalmol. 1997 Jul;81(7):563-7.

Pseudocystic ultrasound appearance of choroidal melanoma.

Pearce IA, Smith PA, Damato BE.

Br J Ophthalmol. 1997 Jun;81(6):517.

Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells.

Pearce IA, Cambray-Deakin MA, Burgoyne RD.

FEBS Lett. 1987 Oct 19;223(1):143-7.

N-methyl-D-aspartate raises cytosolic calcium concentration in rat cerebellar granule cells in culture.

Burgoyne RD, **Pearce IA**, Cambray-Deakin M.

Neurosci Lett. 1988 Aug 15;91(1):47-52.

National/International Invited Lectures

The Future of Therapies and Trials in Geographic Atrophy.
GA Days Annual; Meeting, Rome Apr 2023

Introduction to the Vision Academy
Floretina, Rome Dec 2022

Is the Port Delivery System the answer to AMD in 2022?
Portuguese Retina and Vitreous Society Annual Meeting, Madeira Oct 2022

Future Therapies for Geographic Atrophy
Royal College of Ophthalmologist's Annual Congress, Glasgow May 2022

The "Definitive" Debate: Is OCTA ready to replace FFA ?
Royal College of Ophthalmologist's Annual Congress, Glasgow May 2022

Advances in Ophthalmic Imaging
Royal College of Physicians Annual Congress, April 2022

Challenges in the management of neovascular AMD,
Royal College of Ophthalmologists Seminar Chair and Speaker Mar 2022

Recent advances in GA: Data from Phase 3 clinical trials
Annual Congress Asia-Pacific Vireo-retinal Society December 2021

The risk/ benefit of port delivery system warrants its routine use in neovascular AMD.
EURetina Debate December 2021

The "Definitive" Debate: Is the NHS Ready to Manage Treatment Naïve PDR with only
Intravitreal anti-VEGF Injections?
Royal College of Ophthalmologist's Annual Congress, May 2021

The Power of An EMR In Research – Local, Regional and National Benefits
Heidelberg Virtual Imaging Symposium Oct 2020

Widefield Angiography in Uveitis
Swiss Ophthalmological Socceity, Lausanne Aug 2020

Ultra-widefield Imaging
100% Optical, London Jan 2020

IPCV in Macula Clinics
Royal College of Ophthalmologist's Annual Congress, Glasgow May 2019

Informing DVLA
College of Optometry Annual Meeting Keynote, Birmingham Feb 2019

Chair/DMO Consensus Pathway
Retinal Pioneers Summit, London Jan 2019

Chair/VR On Call Debate

British / Eire Association of Vitreoretinal Surgeons Annual Meeting, Liverpool Nov 2018

Disease Modification: What is the unique treatment goal for doctors/pts with diabetes?

DR Barometer Project European Workshop, Milan Sep 2018

OCTA in nvAMD

Euretina Instructional Course, Vienna Sep 2018

OCTA in DMO – what is the potential ?

Heidelberg 2nd International Masterclass at EURETINA, Vienna Sep 2018

PCV and PEHCR

Royal College of Ophthalmologist's Retinal Diseases Seminar, London July 2018

The use of topical antibiotics for the management of intravitreal injections

Retinal Pioneers Summit, London Jan 2018

PCV – Diagnosis and treatment: What's new?

Royal College of Ophthalmologist's Macular Diseases Seminar, London Dec 2017

Pneumatic Retinopexy Debate

British and Eire Association of Vitreoretinal Surgeons Annual Meeting, Durham Nov 2017

DVLA Notification: Who, When and Why?

SAS Annual meeting, Doncaster Nov 2017

DVLA seminar RCOPHTH

Chair and presenter, London Sept 2017

Real World Evidence in Medical Retina

Bayer Sponsored Australian Lecture Tour, Brisbane/Perth/Sydney Aug 2017

PCV in the UK and the role of PDT

Royal College of Ophthalmologist's Annual Congress, Liverpool May 2017

DRCR.net Clinical Outcomes

Vision Academy Meeting, Barcelona March 2016

Bilateral Anti-VEGF Workshop

Vision Academy Meeting, Barcelona March 2016

Fixed Dosing for AMD

Controversies in Ophthalmology (COPHY), Warsaw April 2016

Mild DME Management

Controversies in Ophthalmology (COPHY), Warsaw April 2016

Preferred Visit Regime for Anti-VEGF Management

Controversies in Ophthalmology (COPHY), Warsaw April 2016

Vitreomacular Interface Disease Management
RCOPHTH Elizabeth Thomas Seminar, Nottingham Dec 2015

OCT Assessment in Inflammatory Eye Diseases
TOPCON National OCT Day, Birmingham Nov 2015

Experience with Ocriplasmin and VMT
Yorkshire Retinal Society Summer Meeting, June 2015

What are the Major Pitfalls in AMD Care ?
Royal College of Ophthalmologist's Annual Congress, Liverpool May 2015

Role of Surgery in Diabetic Macular Oedema
Royal College of Ophthalmologist's Annual Congress, Liverpool May 2015

Is there a Role for Surgery in Uveitis ?
Retina Day
Royal College of Ophthalmologist's Annual Congress, Liverpool May 2015

Imaging in AMD
Oxford Ophthalmological Congress, July 2014

Angiographic Imaging of Inflammatory Choroidal Diseases
Imaging Course
Royal College of Ophthalmologist's Annual Congress, Birmingham May 2014

Developments in the Treatment of AMD
Allied Health Professionals Day
Royal College of Ophthalmologist's Annual Congress, Birmingham May 2014

Surgical vs Pharmacological Resolution of VMT
Retina Day
Royal College of Ophthalmologist's Annual Congress, Birmingham May 2014

Diabetic Retinopathy Management
North of England Ophthalmological Society Summer Meeting Chester Jun 2013

Regular Questions I am asked in the Clinic – RVO Management
Medical Retina Group Annual Meeting Oxford Jun 2013
Impact of CNV Treatment on the Choroid
Royal College of Ophthalmologist's Annual Congress, Liverpool May 2013

MS and Uveitis
Medical Ophthalmological Society UK Annual Congress Glasgow Mar 2013

Uveitis - Has Surgery Any Role ?
Royal College of Ophthalmologist's Seminar, London Feb 2013

Anti-VEGF in Diabetic Macular Oedema Management
Royal College of Ophthalmologist's Seminar, Edinburgh Nov 2012

FFA and ICG Angiography in AMD Decision Making
Retinal Imaging Course Aintree Nov 2012

Cases from The Uveitis Clinics Symposium
Royal College of Ophthalmologist's Annual Congress, Liverpool May 2012

Steroids in Retinal Vein Occlusion Management
Royal College of Ophthalmologist's Annual Congress, Liverpool May 2012

Advances in Intravitreal Therapies : Benefits, Safety, Cost and the NHS
Diabetes UK Annual Congress Glasgow Mar 2012

Retinal Vein Occlusion Management
ScotMacs Meeting Glasgow Mar 2012

New treatment paradigms in RVO
Elizabeth Thomas Seminar Nottingham Nov 2011

New Tools in Remote Monitoring of AMD
11th International Meeting of AMD and Retinal Diseases, Lisbon Nov 2011

Widefield Angiography in Uveitis
9th International Heidelberg Symposium Edinburgh Oct 2011

DMO new treatment paradigms and research
RCOphth Regional DMO Seminar Manchester Sept 2011

Diseases of the Choroid
RCOphth Annual Congress May 2011

ICG Angiography for AMD Decision Making
OIA meeting Harrogate Nov 2010

Intravitreal Therapies for RVO
Retina Sub-Speciality Day RCOphth Annual Congress May 2010 and 2011

Vitrectomy for Diabetes
Yorkshire retinal Society Wakefield Apr 2010

Imaging Techniques in Posterior Uveitis
Manchester Uveitis Symposium March 2010

Epimacular Brachytherapy in Treated AMD
Scandinavian Retina Society Meeting Sweden Dec 2009

ICG Angiography and Wide-field Imaging
Haag Streit UK Meeting Stanstead Dec 2009

How I use VR Surgery in my patients with Diabetic Maculopathy
Retina Regional Speciality Day Frimley Park Nov 2009

ICG Angiography
Oxford Post-Graduate Meeting Nov 2009

FFA and OCT Assessment
Retinal Imaging Course Aintree Nov 2009

Vitrectomy for Diabetes
MSD Meeting Birmingham Oct 2009

ICG Angiography in AMD Decision Making
Yorkshire retinal Society Hull Jun 2009

Use of OCT in the Investigation of Macular Pathology
Edinburg macular Symposium Edinburgh June 2009

Novel Therapies and AMD Management
Nurses Ophthalmic Conference
Aston Business School April 2009

Contemporary Treatments for Diabetic Retinopathy
Nottingham Eye Symposium Nottingham Jan 2009

New Medical Treatments for AMD
RCO Elizabeth Thomas Symposium Nov 2008

Surgery for Diabetic Eye Disease
RCO Seminar Diabetic Retinopathy Oct 2008

Anti-VEGF for non- AMD
RCO Seminar Intravitreal Therapies Apr 2008

VR Surgery in Diabetic Maculopathy
RCOphth Annual Congress May 2007

CJD for VR Surgeons
BEAVRS London Oct 2006

Referees

Professor Rachel Williams
Professor of Ophthalmic Bioengineering
Head of Eye and Vision Science
University of Liverpool
Liverpool
L69 3BX
0151 794 9043

Professor Noemi Lois
Clinical Professor Ophthalmology
School Of Medicine, Dentistry And
Biomedical Sciences
Health Sciences Building
Queens University
Belfast
BT9 7BL
028 9097 6462

Professor Sobha Sivaprasad
Honorary Professor Ophthalmology
Moorfields Eye Hospital
162 City Road
London
EC1V 2PD
020 7566 2039